Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Trade Show, Webcast

Revance to Participate in the Barclays Global Healthcare Conference 2020


Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology pioneer focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection (DAXI), today announced that the company will participate in the Barclays Global Healthcare Conference 2020, in Miami, FL.

President and Chief Executive Officer, Mark Foley, is scheduled to participate in a fireside chat on Tuesday, March 10, at 1:35 p.m. ET.

Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.revance.com. The webcast replay will be available after the conclusion of the live presentation for approximately 30 days.

About Revance Therapeutics, Inc.

Revance Therapeutics is a Silicon Valley-based biotechnology company, pioneering new innovations in neuromodulators for aesthetic and therapeutic indications. Revance's lead product candidate, DaxibotulinumtoxinA for Injection (DAXI), combines a proprietary stabilizing peptide excipient with a highly purified botulinum toxin that does not contain human or animal-based components. Revance has successfully completed a Phase 3 program for DAXI in glabellar (frown) lines and is pursuing U.S. regulatory approval in 2020. Revance is also evaluating DAXI in the full upper face, including glabellar lines, forehead lines and crow's feet, as well as in three therapeutic indications - cervical dystonia, adult upper limb spasticity and plantar fasciitis. Beyond DAXI, Revance gained exclusive rights to commercialize TEOXANE SA's Resilient Hyaluronic Acid® (RHA®) line of fillers in the U.S., the first and only range of FDA-approved dermal fillers for correction of dynamic facial wrinkles and folds. Revance has also begun development of a biosimilar to BOTOX®, which would compete in the existing short-acting neuromodulator marketplace. Revance is dedicated to making a difference by transforming patient experiences. For more information or to join our team visit us at www.revance.com.

"Revance Therapeutics" and the Revance logo are registered trademarks of Revance Therapeutics, Inc.
Resilient Hyaluronic Acid® and RHA® are trademarks of TEOXANE SA.
BOTOX® is a registered trademark of Allergan, Inc.


These press releases may also interest you

at 10:05
AscellaHealth, a global healthcare and specialty pharmacy solutions organization, today released its latest Specialty & Rare Pipeline Digesttm, the industry's most comprehensive quarterly resource of new, pending and upcoming Specialty and Rare...

at 10:02
Liquid Mobile, a rapidly growing on-demand, mobile IV hydration and wellness service, announces the opening of three new locations in Texas, all situated within Cowboys Fit clubs - state-of-the-art fitness facilities in partnership with the Dallas...

at 10:01
ISOPURE, a leading and innovative protein brand and part of Glanbia Performance Nutrition, announced the latest addition to the ISOPURE portfolio: Collagen Peptides. The product supports healthy joints, hair, skin and nails, plus immune support* with...

at 10:00
Turpaz Industries , continues the integrated growth strategy and acquires the Belgian and German Clarys & Willich group. In the purchase agreement reported today, it was stated that the Turpaz Industries group will purchase 100% of the Clarys &...

at 10:00
Right at Home has 700-plus in-home care franchise locations across the U.S. and five other countries. They are looking to expand in La Crosse with a new territory. The investment opportunity allows entrepreneurs to make a difference in their own...

at 10:00
Labroots, the leading scientific networking website and producer of educational virtual events and webinars, is thrilled to announce the 6th Annual Bioprocessing Virtual Event Series, scheduled for April 3rd, 2024. This free, day-long online event...



News published on and distributed by: